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Background: Rheumatoid arthritis (RA) is an inflammatory disease that leads to destruction of both articular
cartilage and bone tissues. In rheumatic joints, synoviocytes and T-lymphocytes as well as bone cells produce the
receptor activator of nuclear factor κ-B (RANK) ligand (RANKL), which binds to RANK on the surface of osteoclasts
and their precursor cells to induce differentiation and activation of osteoclasts. Hence, inhibition of RANKL may be a
promising approach to suppress osteolysis in RA. On the other hand, RANKL production by lymphocytes indicates
the possibility that its inhibition would be effective to suppress inflammation in RA. In addition, it has been reported
that cathepsin K, a predominant cysteine protease in osteoclasts, is involved in cartilage destruction in RA model
mice. Here, we evaluated the effects of an anti-RANKL antibody on inflammation in footpads and degradation of
articular cartilage in RA model mice.
Results: We induced arthritis in mice by injection of anti-type II collagen antibodies and lipopolysaccharide (LPS).
Inhibition of RANKL by an anti-RANKL antibody (OYC1, Oriental Yeast, Tokyo, Japan) was confirmed by increased
bone volume in the metaphysis of tibias. Swelling in either limb until day 14 was seen in 5 of 6 mice injected with
anti-collagen antibodies and LPS without treatment with OYC1, while that was seen in 4 of 5 mice treated with
OYC1. The average arthritis scores on day 14 in those groups were 2.17 and 3.00, respectively, indicating that OYC1
did not ameliorate inflammation in the limbs. Histological analyses indicated that OYC1 does not protect articular
cartilage from destruction in mice with arthritis.
Conclusions: Our present study failed to show the effectiveness of an anti-RANKL antibody to ameliorate inflammation
in the limbs or protect articular cartilage from degradation in a collagen antibody-induced arthritis mouse model.
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Rheumatoid arthritis (RA) is an inflammatory disease that
leads to destruction of both articular cartilage and bone tis-
sues. An articular cavity is a space enclosed by articular car-
tilage and synovial membranes. Single-layered cells compose
a synovial membrane in normal joints, while in RA they* Correspondence: yoichim@dent.showa-u.ac.jp
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unless otherwise stated.proliferate in inflammatory conditions to form a pannus that
destroys both cartilage and bone tissues [1]. It is well known
that osteoblasts and/or osteocytes stimulated by physio-
logical bone-resorbing factors such as activated vitamin D
and parathyroid hormone produce the receptor activator of
nuclear factor κ-B (RANK) ligand (RANKL), which binds to
RANK distributed on the plasma membrane of osteoclasts
and their precursor monocytes/macrophages. Interaction
between RANKL and RANK induces differentiation and
activation of osteoclasts [2,3]. Inflammatory cytokinesLtd. This is an Open Access article distributed under the terms of the Creative
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6, and interleukin-17 induce the expression of RANKL in
osteoblasts, which augments bone destruction by osteoclasts
in inflammatory conditions [4]. In addition, synovial fibro-
blasts and activated T lymphocytes abundantly produce
RANKL, which is considered to contribute to osteoclasto-
genesis in RA [5]. Therefore, inhibition of the interaction be-
tween RANKL and RANK may be a promising approach to
suppress osteolysis in RA. Denosumab, a fully human
monoclonal antibody against RANKL, has been used clinic-
ally for treatment of osteoporosis and bone erosion associ-
ated with multiple myeloma and bone metastasis from
tumors [6,7]. In addition, clinical studies on the effectiveness
of denosumab against RA revealed that denosumab sup-
pressed bone erosion [8].
The RANKL/RANK system functions not only in bones,
but also in various tissues and cells including the immune
system, vascular system, skin, and central nervous system
[9]. The existence of this system in the immune system
suggests that inhibition of RANKL can suppress the onset
of RA and consequently inhibit cartilage degradation. It
has been also reported that cathepsin K, a predominant
cysteine protease in osteoclasts, is expressed in osteoclasts
in contact with articular cartilage in RA patients and stabi-
lized by glycosaminoglycans, such as chondroitin sulfate,
which are abundantly produced by chondrocytes [10,11].
It was also reported that inhibition of cathepsin K sup-
pressed cartilage degradation in collagen-induced arthritis
in mice [12]. In addition, a clinaical study regarding the ef-
fects of denosumab on RA showed a transient decrease in
the blood level of C-terminal telopeptide of type II colla-
gen [8]. These observations suggest that anti-RANKL
antibodies may have potential to inhibit degradation of ar-
ticular cartilage associated with RA.
In the present study, we evaluated the effects of an
anti-RANKL antibody on inflammation in footpads and
degradation of articular cartilage in collagen antibody-
induced arthritis model mice.
Results
Induction of arthritis and validation of anti-RANKL
antibody in mice
We examined the effects of an anti-RANKL antibody on in-
flammation in the joints and degradation of articular cartil-
age using a collagen antibody-induced arthritis mouse
model. Male DBA1/J mice were divided into 4 experimental
groups (6 in each), i.e., RA-/Ab-, RA-/Ab+, RA+/Ab-, and
RA+/Ab+ (Figure 1). RA+ mice were injected with a cocktail
of antibodies to type II collagen and lipopolysaccharide
(LPS) (Chondrex, Inc., Redmond, WA) to induce arthritis.
RA- mice were the control without injection of the collagen
antibodies and LPS. Ab+ indicate that mice belonging to
these groups were treated with the anti-RANKL antibody
(OYC1, Oriental Yeast, Tokyo, Japan). Ab- mice are thecontrol without treatment with the anti-RANKL antibody.
Unfortunately, 1 of the 6 RA+/Ab+mice died within 1 day
after subcutaneous injection of the anti-RANKL antibody
from peritonitis possibly caused by an inappropriate intra-
peritoneal injection of the anesthetic agent.
μCT analyses indicated that administration of OYC1 anti-
RANKL antibody increased bone mass both in tibias from
RA- and RA+ mice (Figure 2A). The bone volume fraction
(BV/TV) of trabecular bone in tibias from mice injected
with the OYC1 anti-RANKL antibody (RA-/Ab+mice) was
significantly greater as compared to that in RA-/Ab- mice
(Figure 2B). The same effect of the antibody was observed
in RA+ mice (Figure 2C). Trabecular thickness (Tb.Th) was
not affected by OYC-1 anti-RANKL antibody in either RA-
or RA+ group (Figure 2D, E). While OYC1 antibody did not
change trabecular number (Tb.N) in RA- mice (Figure 2F),
the antibody significantly increased Tb.N in RA+ mice
(Figure 2G). While trabecular space (Tb.Sp) tended to de-
cline in mice received the anti-RANKL antibody in both
RA- and RA+ groups, the effect of the antibody on Tb.Sp
was not significant (Figure 2H, I). These quantitative μCT
analyses indicated that the amount of OYC1 anti-RANKL
antibody administered (5 mg/kg) was sufficient for inhib-
ition of RANKL in our experimental model, as previously
reported [13].
Ineffectiveness of anti-RANKL antibody on inflammation
induced by anti-collagen antibodies
We measured the footpad thickness of 4 limbs daily after
injection of a cocktail of antibodies to type II collagen.
Additional file 1: Figure S1 shows change in the thickness
of each paw of the individual mice. Thickness of footpads
was hardly changed in RA- mice in either Ab- or Ab+
group (Additional file 1: Figure S1A, C, E, G). On the other
hand, some of the mice injected with a cocktail of anti-
bodies to type II collagen on day 0 and LPS on day 3
showed swelling in the paws, especially those in fore limbs
of both Ab- and Ab+mice (Additional file 1: Figure S1B, D).
Change in the thickness of hind paws was small (Additional
file 1: Figure S1F, H). Then we summarized the frequency of
swelling in each paw of the individual mouse observed
14 days after injection of anti-type II collagen antibodies
(Table 1). Swelling frequency in either limb until day 14 in
the RA+/Ab- group occurred in 5 of the 6 mice, whereas
that was seen in 4 of 5 in the RA+/Ab+ group.
We also determined the arthritis score of mice every-
day as an index of severity of inflammation based on the
frequency and extent of swelling and reddening in the
limbs. The RA score for RA- mice did not increase irre-
spective of whether they were given anti-RANKL anti-
body (RA-/Ab+) or not (RA-/Ab-). On the other hand,
the average arthritis score for the RA+/Ab- mice on day
12 was 2.17 ± 1.33 (mean ± SD), while that for the RA
+/Ab+ mice was 3.00 ± 0 (Figure 3). These results show
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Limbs Histological analysisMice on day 14:
Figure 1 Experimental design. Eight-week-old male DBA1/J mice were divided into 4 groups (6 in each), i.e., RA-/Ab-, RA-/Ab+, RA+/Ab-, and
RA+/Ab+. A cocktail of anti-type II collagen antibodies and E. coli LPS was injected intra-peritoneally into the RA+ mice on days 0 and 3,
respectively. RA- mice were the control without injection of the anti-type II collagen antibodies and LPS. The OYC1 anti-RANKL monoclonal
antibody (5 mg/kg) was injected subcutaneously into the Ab+mice on day 5. Ab- mice were the control without injection the anti-RANKL
antibody. Arthritis scores were determined daily from day 0 to 14. The 4 limbs were removed on day 14 for analysis of histological changes
in the joints.
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have an effect to suppress inflammation induced by anti-
bodies against type II collagen and LPS.
Representative histological images of limb joints are
shown in Figure 4. Synovial thickening, one of the typical
changes seen in joints affected by RA, was observed in joints
from both the RA+/Ab- (Figure 4C, G, K, O) and RA+/Ab+
(Figure 4D, H, L, P) mice. No significant difference was
seen in regard to synovial thickening or infiltration of
inflammatory cells in the RA+/Ab- mice and RA+/Ab+
mice, indicating that synovitis was not ameliorated by
administration of the anti-RANKL antibody.Ineffectiveness of anti-RANKL antibody on degradation of
cartilage induced by anti-collagen antibodies
Representative magnified images of articular cartilage
from forelimbs of the RA-/Ab-, RA-/Ab+, RA+/Ab-, and
RA+/Ab+mice are shown in Figures 5A-D. The articu-
lar cartilage surface in the RA-/Ab- and RA-/Ab+mice
had a smooth and clean appearance (Figure 5A, B),
whereas erosion was evident in that from RA+ mice
irrespective of anti-RANKL antibody administration
(Figure 5C, D). Cartilage matrix stained with Safranin O
was reduced in RA+ mice (Figure 5C, D) in comparison
with that in RA- mice (Figure 5A, B). Anti-RANKL anti-
body did not ameliorate the loss of cartilage matrix in
RA+ mice (Figure 5C, D). These findings indicated that
the OYC1 anti-RANKL antibody did not provide a pro-
tective effect on cartilage in the present collagen antibody-
induced arthritis model.Discussion
Denosumab, a fully human monoclonal antibody against
RANKL, is used clinically for treatment of osteoporosis
and bone erosion associated with multiple myelomas and
bone metastasis from those tumors [6,7]. In addition, the
effectiveness of denosumab for treatment of bone erosion
in RA is promising. On the other hand, degradation of ar-
ticular cartilage is another serious problem encountered
in patients with RA. Since it is known that RANKL par-
ticipates in immunological reactions [14] and cathepsin
K, one of the major proteases secreted by osteoclasts, is
involved in cartilage degradation [12], it is important to
determine if inhibition of RANKL can ameliorate cartilage
degradation in RA. In the present study, we examined the
effects of an anti-RANKL antibody on inflammation
and cartilage degradation in a mouse model of RA in-
duced by injection of a cocktail of antibodies to type II
collagen.
We employed an RA model in mice produced by in-
jection of antibodies against type II collagen and LPS to
evaluate effectiveness of treatment with anti-RANKL
antibody. Swelling of the paws (Table 1 and Additional
file 1: Figure S1), increment in the RA score (Figure 3),
and accumulation of inflammatory cells in the joints
(Figure 4) indicated that inflammation was induced in
the limbs by the treatments with antibodies against type
II collagen and LPS. Reduced staining with Safranin O
and the rough surface of the articular cartilage also sug-
gested the degradation of the cartilage matrix in the
joints in RA+ mice (Figure 5). Hence it is considered to
be appropriate to use this model for evaluation of the
Figure 2 Effect of anti-RANKL antibody OYC1 on morphology of
tibias in RA- and RA+ mice. Tibias excised from RA-/Ab-, RA-/Ab+,
RA+/RA-, and RA+/Ab+mice were subjected to three-dimensional
micro-computed tomography. (A) Representative images of metaphysis
of tibias. Bars: 600 μm. Trabecular bone volume (BV/TV) (B, C), trabecular
thickness (Tb.Th) (D, E), trabecular number (Tb.N) (F, G), and trabecular
space (Tb.Sp) (H, I) in the metaphysis of tibias from RA- (B, D, F, H) and
RA+ (C, E, G, I)mice was quantified. Data are shown as the mean± SD
(n = 6). Mann-Whitney U-test was used for statistical analysis. Significant
differences are indicated in their p-values. NS shows that the difference
between the groups is not significant.
Table 1 Frequency of swelling in limb pads
Group Fore limb Hind limb Total
Left Right Left Right
RA-/Ab- 0/6 0/6 0/6 0/6 0/6
RA-/Ab+ 0/6 0/6 0/6 0/6 0/6
RA+/Ab- 1/6 5/6 1/6 0/6 5/6
RA+/Ab+ 4/5 3/5 1/5 1/5 4/5
Development of inflammation in the 4 limbs was evaluated daily by
measuring the thickness of each footpad (Additional file 1: Figure S1).
Occurrence of swelling in the limbs until day 14 is shown as a fraction, with
the numerator and denominator representing the number of mice with
swollen limb(s) and total number of mice in the group, respectively.
Figure 3 Change in arthritis score after injection of antibodies
to type II collagen. Arthritis scores were determined daily after
injection of a cocktail of antibodies to type II collagen according to
the following criteria: 0, normal; 1, mild but definite redness and
swelling of the ankle or wrist, or apparent redness and swelling
limited to individual digits regardless of the number of affected
digits; 2, moderate redness and swelling of ankle and wrist; 3, severe
redness and swelling of the entire paw including digits; 4, maximally
inflamed limb with involvement of multiple joints. Data are
expressed as the mean ± SD. There was no statistical difference
between RA+/Ab- group and RA+/Ab+ group (Steel-Dwass test).
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tilage degeneration in RA.
It was previously reported that the OYC1 anti-RANKL
antibody was effective to suppress osteoclast formation in
mice from 1 to at least 28 days after subcutaneous injec-
tion at a dose of 5 mg/kg of body weight [13]. In the
present study, the value for BV/TV in the metaphysis oftibias was significantly increased by subcutaneous injec-
tion of the same dose of the OYC1 anti-RANKL antibody
(Figure 2B, C), demonstrating that the activity of RANKL
was also suppressed by OYC1 in our experimental model.
Hence, the inability of this antibody to reduce inflamma-
tion in synovial membranes and degradation of articular
cartilage is not due to insufficient inhibition of RANKL.
Osteoprotegerin (OPG), a soluble decoy receptor for
RANKL, is secreted by osteoblasts and other types of cells
and inhibits interaction between RANKL and RANK by
binding to the former [15,16]. There are several reports of
the effects of OPG administration on the pathogenesis of
RA in animal models [17-20], including findings that bone
erosion and osteoclast functions were down-regulated by
treatment with OPG, whereas that did not have a significant
effect on inflammation or cartilage erosion [20]. Those re-
ports and the present results indicate that the contribution
Figure 4 Histological analyses of limb joints. The 4 limbs were excised from all mice at 14 days after injection of a cocktail of antibodies to type II
collagen. Decalcified 8-μm sections of hands (A-D), elbows (E-F), toes (I-L), and knees (M-P) from RA-/Ab- (A, E, I, M), RA-/Ab+ (B, F, J, N), RA+/Ab-
(C, G, K, O), and RA+/Ab+ (D, H, L, P)mice were stained with hematoxylin and eosin. Synovial thickening and accumulation of inflammatory cells were
observed in joints from the RA+ mice (arrowheads in panels C, D, G, H, K, L. O, and P). Bars: 500 μm (A-D, I-P) and 200 μm (E-H).
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small.
Although human studies are required for evaluation of
the effects of denosumab on cartilage erosion, the present
animal study findings suggest that inhibition of RANKL
by its antibodies is not effective for protection of articular
cartilage from degradation associated with RA.Figure 5 Effect of anti-RANKL antibody OYC1 on cartilage
erosion induced by collagen antibodies. (A-D) Representative
images of articular cartilage of joints in hands from RA-/Ab- (A), RA-/
Ab+ (B), RA+/Ab- (C), and RA+/AB+ (D) mice were stained with Fast
Green and Safranin O. Note that cartilage matrix stained pink-red by
Safranin O diminished and the erosion on the surface of cartilage
was observed in the joints from RA+/Ab- and RA+/Ab+mice.
Bars: 20 μm.Conclusion
The anti-RANKL antibody OYC1 did not protect articu-
lar cartilage from degradation in collagen antibody-
induced arthritis model mice, despite inhibition of




An Arthrogen-CIA® 5-clone cocktail kit with LPS from
Escherichia coli O111:B4 (Chondrex) was used for in-
duction of collagen antibody-induced arthritis in mice.
The anti-mouse RANKL monoclonal antibody (OYC1)
was obtained from Oriental Yeast Co., Ltd. An animal
COMP ELISA kit was purchased from AnaMar AB
(Göteborg, Sweden). All other chemicals and reagents
were obtained from commercial sources.
Mice and experimental groups
Eight-week-old male DBA1/J mice (Japan SLC, Inc.,
Shizuoka, Japan) were randomly divided into 4 groups
(6 in each), i.e., RA-/Ab-, RA-/Ab+, RA+/Ab-, and
RA+/Ab+ (Table 1). Mice in the RA+ groups were given
an intra-peritoneal injection of a cocktail of 5 clones of
mouse monoclonal anti-type II collagen antibodies
(1.5 mg/0.15 mL/head) on day 0, followed by an intra-
peritoneal injection of E. coli LPS (50 μg/0.1 mL/head) on
day 3 according to the manufacturer’s instruction
(Chondrex). RA- mice were the control without injection
of the anti-type II collagen antibodies and LPS. The OYC1
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was injected subcutaneously into mice in the Ab+ groups
on day 5, while mice in the Ab- groups were not given that
treatment. All mice were housed in a specific pathogen-free
environment, and given free access to food and water. All
experiments performed in this study were approved by the
Ethical Board for Animal Experiments of Showa University,
Tokyo, Japan (approval number: 14011).
Scoring of RA
We observed mice daily for development of inflammation
in the 4 limbs from day 0 to 14. The thickness of each
footpad was measured using a slide caliper. In addition,
the severity of inflammation was scored according to the
criteria of Chondrex, as follows: 0, normal; 1, mild but def-
inite redness and swelling of the ankle or wrist, or appar-
ent redness and swelling limited to individual digits
regardless of the number of affected digits; 2, moderate
redness and swelling of ankle and wrist; 3, severe redness
and swelling of the entire paw including digits; 4, max-
imally inflamed limb with involvement of multiple joints.
X-ray micro-tomography
After blood sampling, all 4 limbs were dissected and fixed
in 4% paraformaldehyde (pH 7.4). The tibias were sub-
jected to three-dimensional micro-computed tomography.
Three-dimensional microstructural image data obtained
were reconstructed using TRI/3D-BON software (Ratoc
System Engineering Co., Ltd., Tokyo, Japan).
Histological examinations
The fixed limbs were decalcified in a decalcifying solution
from Wako Pure Chemicals Co., Ltd. (Osaka, Japan) and
embedded in paraffin. They were finally sliced into 8-μm
sections, stained with hematoxylin and eosin, and ob-
served under a microscope. For observation of the articu-
lar cartilage, the sections were stained with 0.1% Fast
Green for 5 minutes, rinsed with 1% acetic acid for 10 sec-
onds, and stained with Safranin O for 5 minutes.
Statistical analyses
Results are expressed as the mean ± SD. A Mann-
Whitney U test and Steel-Dwass test were used for stat-
istical analyses, with P values less than 0.05 considered
to be significant.
Additional file
Additional file 1: Figure S1. Effect of anti-RANKL antibody on change
in the thickness of footpads in mice with or without injection of a cock-
tail of anti-type II collagen antibodies. DBA1/J mice in the RA+ groups
were given an intra-peritoneal injection of a cocktail of 5 clones of mouse
monoclonal anti-type II collagen antibodies (Chondrex) on day 0,
followed by an intra-peritoneal injection of E. coli LPS on day 3. RA- mice
were the control without injection of the anti-type II collagen antibodiesand LPS. The OYC1 anti-RANKL monoclonal antibody was injected
subcutaneously into mice in the Ab+ groups on day 5, while mice in the
Ab- groups were not given that treatment. The thickness of each footpad
was measured daily from day 0 to day 14. Change in the thickness of
each footpad was plotted as a line for individual mice. The left panels
show the results from RA- mice (A, C, E, G), and the right panels are those
from RA+ mice (B, D, F, H). Dotted and solid lines indicate the values
obtained in Ab- and Ab+mice, respectively. Results from left front paws
(A, B), right front paws (C, D), left hind paws (E, F), and right hind paws
(G, H) were indicated as separate figures.
Abbreviations
RA: Rheumatoid arthritis; RANK: Receptor activator of nuclear factor κ-B;
RANKL: RANK ligand; LPS: Lipopolysaccharide; BV/TV: Bone volume fraction;
OPG: Osteoprotegerin.
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